CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors


SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.

Read more:
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

Related Posts